Search - tctmd.com

Displaying 221 - 240 of 247

Sort: Relevancy | Date

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Presenter: Krzysztof Bartus, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

TCT 26: Long-term Event Rates for Left Atrial Appendage Closure With WATCHMAN: PROTECT AF Five-Year and PREVAIL Three-Year Follow-up

Presenter: Zahid Amin, Jacqueline Saw, Vivek Y. Reddy

October 31, 2016

Presentation TCT 2016

TransMitral Valve Replacement (VIV) Within a St. Jude Mechanical Mitral Valve

Presenter: Danny Dvir, Marco Moscarelli, J. Bradley Oldemeyer

October 31, 2016

Presentation TCT 2016

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Jamil Abdalla Saad

October 30, 2016

Presentation TCT 2016

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Josep Rodés-Cabau

October 30, 2016

Presentation TCT 2016

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Yat-Yin Lam

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Horst Sievert

October 30, 2016

Presentation TCT 2016

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Apostolos Tzikas

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Martin W. Bergmann

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

Transcatheter Valve Replacement for Mitral Bioprosthetic Valve Failures: Multicenter VIVID Registry Results

Presenter: Michael J. Mack, Francesco Maisano, Danny Dvir

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

Un Sistema Simple de Puntuación del Riesgo Predice la Mortalidad Post-TAVR

Michael O'Riordan

July 25, 2016

Advertisement

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

TCT 26: Long-term Event Rates for Left Atrial Appendage Closure With WATCHMAN: PROTECT AF Five-Year and PREVAIL Three-Year Follow-up

TransMitral Valve Replacement (VIV) Within a St. Jude Mechanical Mitral Valve

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Transcatheter Valve Replacement for Mitral Bioprosthetic Valve Failures: Multicenter VIVID Registry Results

TCTMD’s Top 10 Most Popular Stories for September 2016

Un Sistema Simple de Puntuación del Riesgo Predice la Mortalidad Post-TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content